JP2020537525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537525A5 JP2020537525A5 JP2020521290A JP2020521290A JP2020537525A5 JP 2020537525 A5 JP2020537525 A5 JP 2020537525A5 JP 2020521290 A JP2020521290 A JP 2020521290A JP 2020521290 A JP2020521290 A JP 2020521290A JP 2020537525 A5 JP2020537525 A5 JP 2020537525A5
- Authority
- JP
- Japan
- Prior art keywords
- replicative
- vector according
- saladenovirus
- vector
- expression cassette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 claims description 49
- 230000003362 replicative effect Effects 0.000 claims description 25
- 241000282693 Cercopithecidae Species 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 241000701161 unidentified adenovirus Species 0.000 claims description 20
- 241000282577 Pan troglodytes Species 0.000 claims description 8
- 108700019146 Transgenes Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000001124 posttranscriptional effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 108700026758 Adenovirus hexon capsid Proteins 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 241001217856 Chimpanzee adenovirus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 208000010772 Dog disease Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572927P | 2017-10-16 | 2017-10-16 | |
| US62/572,927 | 2017-10-16 | ||
| PCT/EP2018/078206 WO2019076877A1 (en) | 2017-10-16 | 2018-10-16 | ADENOVIRAL VECTORS FOR REPLICATION |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537525A JP2020537525A (ja) | 2020-12-24 |
| JP2020537525A5 true JP2020537525A5 (enExample) | 2021-11-18 |
| JPWO2019076877A5 JPWO2019076877A5 (enExample) | 2022-06-20 |
Family
ID=63965644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521290A Pending JP2020537525A (ja) | 2017-10-16 | 2018-10-16 | 複製能力のあるアデノウイルスベクター |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11268108B2 (enExample) |
| EP (1) | EP3697899A1 (enExample) |
| JP (1) | JP2020537525A (enExample) |
| KR (1) | KR20200066349A (enExample) |
| CN (1) | CN111655847A (enExample) |
| AR (1) | AR113450A1 (enExample) |
| AU (1) | AU2018351308B2 (enExample) |
| BR (1) | BR112020007238A2 (enExample) |
| CA (1) | CA3079043A1 (enExample) |
| EA (1) | EA202090700A1 (enExample) |
| IL (1) | IL273753A (enExample) |
| MX (1) | MX2020003385A (enExample) |
| SG (1) | SG11202003058UA (enExample) |
| WO (1) | WO2019076877A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021025025A2 (pt) | 2019-06-11 | 2022-02-22 | Glaxosmithkline Biologicals Sa | Formulações de vacinas de mucosa |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| US20230109362A1 (en) | 2020-05-14 | 2023-04-06 | Glaxosmithkline Biologicals Sa | Viral biosensors |
| CN114591922A (zh) * | 2022-03-30 | 2022-06-07 | 长睿生物技术(成都)有限公司 | 一种表达狂犬病毒g蛋白的重组黑猩猩源腺病毒及其制备方法 |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998010087A1 (en) * | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| MX2011007980A (es) | 2009-02-02 | 2011-08-17 | Okairos Ag | Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas. |
| US8865182B2 (en) * | 2009-07-31 | 2014-10-21 | Paxvax, Inc. | Adenoviral-based vectors |
| JP6091435B2 (ja) | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| GB201322851D0 (en) * | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| EA038402B9 (ru) | 2015-06-12 | 2021-09-22 | Глаксосмитклайн Байолоджикалс Са | Аденовирусные полинуклеотиды и полипептиды |
| GB201513010D0 (en) * | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| GB201620968D0 (en) * | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
-
2018
- 2018-10-16 SG SG11202003058UA patent/SG11202003058UA/en unknown
- 2018-10-16 KR KR1020207013668A patent/KR20200066349A/ko not_active Withdrawn
- 2018-10-16 BR BR112020007238-9A patent/BR112020007238A2/pt not_active IP Right Cessation
- 2018-10-16 AU AU2018351308A patent/AU2018351308B2/en not_active Expired - Fee Related
- 2018-10-16 AR ARP180103004A patent/AR113450A1/es not_active Application Discontinuation
- 2018-10-16 CA CA3079043A patent/CA3079043A1/en active Pending
- 2018-10-16 MX MX2020003385A patent/MX2020003385A/es unknown
- 2018-10-16 EP EP18792880.9A patent/EP3697899A1/en active Pending
- 2018-10-16 EA EA202090700A patent/EA202090700A1/ru unknown
- 2018-10-16 JP JP2020521290A patent/JP2020537525A/ja active Pending
- 2018-10-16 CN CN201880080955.9A patent/CN111655847A/zh active Pending
- 2018-10-16 WO PCT/EP2018/078206 patent/WO2019076877A1/en not_active Ceased
- 2018-10-16 US US16/756,376 patent/US11268108B2/en active Active
-
2020
- 2020-04-01 IL IL273753A patent/IL273753A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537525A5 (enExample) | ||
| Travieso et al. | The use of viral vectors in vaccine development | |
| Humphreys et al. | Novel viral vectors in infectious diseases | |
| Kosinska et al. | Therapeutic vaccination for chronic hepatitis B | |
| Mühlebach | Vaccine platform recombinant measles virus | |
| JP2019526580A5 (enExample) | ||
| Kuate et al. | Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies | |
| JP2017515508A5 (enExample) | ||
| Reynolds et al. | Virus-like vesicle-based therapeutic vaccine vectors for chronic hepatitis B virus infection | |
| Hasanpourghadi et al. | COVID-19 vaccines based on adenovirus vectors | |
| JP2020516264A5 (enExample) | ||
| JP2009539965A5 (enExample) | ||
| JP2016539946A5 (enExample) | ||
| JP2013507107A5 (enExample) | ||
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
| Hanke | New vector and vaccine platforms: mRNA, DNA, viral vectors | |
| JP2021500880A5 (enExample) | ||
| JP2020537526A5 (enExample) | ||
| Flaxman et al. | Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse | |
| Bassi et al. | Vaccination with replication deficient adenovectors encoding YF-17D antigens induces long-lasting protection from severe yellow fever virus infection in mice | |
| RU2639504C2 (ru) | Химерные антигены для вакцины против вируса гепатита с | |
| JP4989224B2 (ja) | Ｄｎａワクチン組成物およびその使用方法 | |
| JPWO2019076877A5 (enExample) | ||
| DK177298B1 (en) | Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and their Use as Vaccines | |
| JP2011506606A (ja) | フィロウイルスまたはアレナウイルス感染の暴露前または暴露後の治療法 |